COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,550 Articles (22,881 medRxiv, 8,669 bioRxiv)

Most recent first Previous |  Page 709: Articles 7081-7090  | Next

Spatio-temporal characteristics of the SARS-CoV-2 Omicron variant spread at fine geographical scales, and comparison to earlier variants
Wood, A. J., Sanchez, A. R., Bessell, P. R., Kao, R. R.
10.1101/2022.08.03.22278013 — Posted: 2022-08-04
Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinations
Hisamatsu, D., Ikeda, A., Ito, L., Matsushita, Y., Hiki, M., Mori, H., Tabe, Y., Naito, T., Akazawa, C.
10.1101/2022.08.03.22278353 — Posted: 2022-08-03
Effects of allocation concealment and blinding in trials addressing treatments for COVID-19: A methods study
Zeraatkar, D., Pitre, T., Diaz-Martinez, J. P., Chu, D., Rochwerg, B., Lamontagne, F., Kum, E., Qasim, A., Bartoszko, J. J., Brignardello-Petersen, R.
10.1101/2022.08.03.22278348 — Posted: 2022-08-03
Real-life evaluation of a rapid antigen test (DPP SARS-CoV-2 Antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the Omicron-dominant wave in Brazil
Bezerra, M. F., Silva, L. C. A., Pessoa-e-Silva, R., Lino, G., Dezordi, F. Z., Lima, G. B., de Lima, R. E., Campos, T., Docena, C., Oliveira, A., Pitta, M. G. d. R., da Silva, F. d. A. S., Pereira, M., Wallau, G. L., Paiva, M. H. S.
10.1101/2022.08.02.22278277 — Posted: 2022-08-03
Nano assembly of plasmonic probe-virus particles enabled rapid and ultrasensitive point-of-care SARS-CoV-2 detection
Park, Y., Ryu, B., Ki, S., Chen, M., Liang, X., Kurabayashi, K.
10.1101/2022.08.01.22278286 — Posted: 2022-08-03
Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: a registry-linkage study
Andrejko, K. L., Myers, J. F., Fukui, N., Nelson, L., Zhao, R., Openshaw, J., Watt, J. P., Jain, S., Lewnard, J. A., Pry, J. M., California COVID-19 Case-Control Study Team
10.1101/2022.08.02.22278300 — Posted: 2022-08-03
Immune response against SARS-CoV-2 of primary healthcare personnel in a commune of Santiago, Chile: follow-up at 6 months.
Olea Normandin, A., Matute, I., Hirmas, M., Gonzalez-Wiedmaier, C., Iruretagoyena, M., Munita, J., Pedroni, E., Gomez, M. I., Cortes, L. J., Hormazabal, J.
10.1101/2022.08.03.22278369 — Posted: 2022-08-03
Cellular and humoral immunity towards parental SARS-CoV-2 and variants of concern after two doses of the NVX-CoV2373-vaccine in comparison to homologous BNT162b and mRNA1273 regimens
Hielscher, F., Schmidt, T., Klemis, V., Wilhelm, A., Marx, S., Abu-Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Sester, U., Widera, M., Sester, M.
10.1101/2022.08.02.22278342 — Posted: 2022-08-03
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review.
Senefeld, J., Franchini, M., Mengoli, C., Cruciani, M., Zani, M., Focosi, D., Casadevall, A., Joyner, M. J.
10.1101/2022.08.03.22278359 — Posted: 2022-08-03
Geospatial disparities in federal COVID-19 test-to-treat program
Smith, E. R., Oakley, E. M.
10.1101/2022.08.02.22278349 — Posted: 2022-08-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).